Please try another search
Siegfried Holding AG, together with its subsidiaries, provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide. It offers pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale-up and clinical trial material production services. The company develops and produces APIs and intermediates, as well as finished dosage forms, including solid oral dosage forms, sterile and aseptic filling injectables, ophthalmics, and inhalative products. In addition, it provides APIs and controlled substances focusing on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition; exclusive synthesis services comprising process and chemical development, analytical development, pilot manufacturing and scale-up, and commercial manufacturing; and viral vector manufacturing solutions. Further, the company licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for products. Siegfried Holding AG was founded in 1873 and is headquartered in Zofingen, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
Andreas Ignaz Casutt | 59 | 2010 | Independent Non-Executive Chairman |
Isabelle Welton | 60 | 2020 | Independent Non-Executive Director |
Beat R. Walti | 55 | 2022 | Independent Director |
Alexandra Brand | 52 | 2022 | Independent Director |
Wolfram Carius | 62 | 2014 | Independent Non-Executive Director |
Elodie Carr-Cingari | 49 | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review